PANK1 — Pantothenate Kinase 1

Introduction

Pank1 — Pantothenate Kinase 1 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

flowchart TD
    PANK1["PANK1"] -->|"regulates"| CoA_biosynthesis["CoA biosynthesis"]
    PANK1["PANK1"] -->|"activates"| PANX1["PANX1"]
    PANK1["PANK1"] -->|"activates"| TGM2["TGM2"]
    PANK1["PANK1"] -->|"activates"| PPAR["PPAR"]
    PANK1["PANK1"] -->|"associated with"| PPAR["PPAR"]
    PANK1["PANK1"] -->|"associated with"| TGM2["TGM2"]
    PANK1["PANK1"] -->|"regulates"| Lipid_Metabolism["Lipid Metabolism"]
    PANK1["PANK1"] -->|"activates"| Actin["Actin"]
    PANK1["PANK1"] -->|"participates in"| lipid_metabolism["lipid metabolism"]
    PANK1["PANK1"] -->|"regulates"| PPAR["PPAR"]
    PANK1["PANK1"] -->|"activates"| LIPID_METABOLISM["LIPID METABOLISM"]
    PANK1["PANK1"] -->|"activates"| Nephropathy["Nephropathy"]
    PANK1["PANK1"] -->|"regulates"| Proteins["Proteins"]
    PANK1["PANK1"] -->|"activates"| Proteins["Proteins"]
    style PANK1 fill:#4fc3f7,stroke:#333,color:#000

PANK1 encodes pantothenate kinase 1, the rate-limiting enzyme in coenzyme A (CoA) biosynthesis. Located on chromosome 10q23.31, PANK1 catalyzes the ATP-dependent phosphorylation of vitamin B5 (pantothenate) to produce phosphopantothenate, the first and rate-limiting step in the CoA biosynthetic pathway^[1]. Mutations in PANK1 cause Pantothenate Kinase-Associated Neurodegeneration (PKAN), a recessive autosomal disorder and the most common form of Neurodegeneration with Brain Iron Accumulation (NBIA), accounting for approximately 50% of all NBIA cases^[2].

Protein Structure and Function

Enzyme Architecture

PANK1 is a cytosolic enzyme belonging to the pantothenate kinase family. The protein contains:

• N-terminal domain: Regulatory region with feedback inhibition sites

• Catalytic core: ATP-binding pocket and pantothenate-binding site

• C-terminal domain: Dimerization interface for tetramer formation

The active tetrameric form of PANK1 requires proper dimerization for catalytic activity. Each monomer contains a conserved kinase fold that binds both ATP and pantothenate substrates^[3].

Coenzyme A Biosynthesis Pathway

PANK1 initiates the CoA biosynthesis pathway:

1. Pantothenate phosphorylation: PANK1 converts pantothenate → phosphopantothenate (using ATP)

2. Cysteine addition: PANK2/4 convert phosphopantothenate → phosphopantothenoylcysteine

3. Decarboxylation: PANK2/4 convert → pantetheine

4. Phosphorylation: COQ8B/PANK3 convert pantetheine → pantetheine 4’-phosphate

5. Final step: Conversion to coenzyme A via COQ8A/B

CoA serves as an essential cofactor for over 100 enzymatic reactions, including:

• Fatty acid synthesis and oxidation

• TCA cycle enzyme function

• Acetylcholine synthesis

• Protein acetylation modifications

Brain Expression and Localization

PANK1 exhibits highest expression in the liver, but is also expressed in various brain regions:

• Cerebral cortex: Pyramidal neurons and interneurons

• Hippocampus: CA1-CA3 regions, dentate gyrus granule cells

• Basal ganglia: Striatum, globus pallidus

• Cerebellum: Purkinje cells and granule cells

• Substantia nigra: Dopaminergic neurons

Expression is particularly high in regions with high metabolic demand and in neurons susceptible to iron accumulation in PKAN patients^[4].

Disease Associations

Pantothenate Kinase-Associated Neurodegeneration (PKAN)

PKAN is an autosomal recessive neurodegenerative disorder caused by biallelic PANK1 mutations. It is characterized by:

Clinical Features:

• Early-onset progressive dystonia (typically before age 10)

• Dysarthria (slurred speech)

• Dysphagia (difficulty swallowing)

• Pigmentary retinopathy (vision loss)

• Cognitive impairment (variable)

• Axonal neuropathy (in some cases)

Two Clinical Forms:

1. Classic PKAN: Early onset (ages 2-4), rapid progression

2. Atypical PKAN: Later onset (adolescence/young adulthood), slower progression

Genetic Spectrum:

• Over 100 pathogenic variants identified

• Most common: G521R, A628T, D665Y

• Genotype-phenotype correlations exist but are imperfect

Neurodegeneration with Brain Iron Accumulation (NBIA)

PKAN represents the most common form of NBIA, a group of disorders characterized by:

• Iron accumulation in the globus pallidus and substantia nigra

• Progressive movement disorders

• Neurodegeneration

The iron accumulation in PKAN results from impaired CoA-dependent processes that affect iron metabolism and mitochondrial function^[5].

Pathogenic Mechanisms

CoA Deficiency

PANK1 loss-of-function leads to cellular CoA deficiency, causing:

1. Mitochondrial dysfunction: Impaired TCA cycle function and ATP production

2. Fatty acid metabolism defects: Reduced β-oxidation

3. Neurotransmitter synthesis: Impaired acetylcholine and GABA synthesis

4. Protein acylation abnormalities: Dysregulated lysine acetylation

Iron Homeostasis Disruption

CoA deficiency disrupts iron metabolism through:

• Altered iron-sulfur cluster assembly

• Impaired mitochondrial iron handling

• Dysregulated ferritin expression

• Increased iron accumulation in vulnerable brain regions

Oxidative Stress

The combination of mitochondrial dysfunction and iron accumulation leads to:

• Increased reactive oxygen species (ROS) production

• Lipid peroxidation

• Protein oxidation

• Neuronal death in the globus pallidus and substantia nigra

Therapeutic Approaches

CoA Bypass Therapy

Pantethine: A stable derivative of pantetheine (CoA precursor) that can bypass the metabolic block:

• Shows promise in cellular and animal models

• Clinical trials ongoing

• May reduce disease progression if administered early

Symptomatic Treatments

Experimental Approaches

• Gene therapy: AAV-PANK2 (for related PKAN) in clinical trials; PANK1 approaches in development

• CoA-enhancing compounds: Small molecules to increase CoA levels

• Iron chelation: Deferoxamine trials (limited efficacy)

• Neuroprotective agents: Under investigation

Animal Models

Pank1 Knockout Mice

• Phenotype: Develop movement abnormalities, reduced CoA levels

• Brain findings: Iron accumulation in basal ganglia

• Utility: Testing therapeutic interventions

Zebrafish Models

• Morphant studies: Recapitulate PKAN phenotypes

• Drug screening: Used to identify CoA-enhancing compounds

Interaction Network

PANK1 interacts with:

Diagnostic Testing

Genetic Testing

• Sequencing: Full gene sequencing for mutation identification

• Deletion/duplication analysis: For copy number variants

• Newborn screening: Not currently standard

Biomarkers

• CoA levels: Reduced in patient cells

• Oxidative stress markers: Elevated in plasma/CSF

• Neuroimaging: MRI shows “eye-of-the-tiger” sign in globus pallidus

Research Directions

1. CoA bypass therapies: Clinical trials of pantethine and derivatives

2. Gene replacement: Developing AAV-based gene therapy

3. Biomarkers: Identifying disease progression markers

4. Natural history studies: Understanding disease variability

5. Combination therapies: Multi-target approaches

Key Publications

1. Zhou B, et al. (2001). A novel pantothenate kinase from Schizosaccharomyces pombe. J Biol Chem. ^{1CitationPMID 11447288Open reference}(https://pubmed.ncbi.nlm.nih.gov/11447288/)

2. Hayflick SJ, et al. (2002). Genetic heterogeneity among patients with pantothenate kinase-associated neurodegeneration. N Engl J Med. ^{2CitationPMID 12480672Open reference}(https://pubmed.ncbi.nlm.nih.gov/12480672/)

3. Zheng H, et al. (2018). Structure of human pantothenate kinase in complex with CoA derivatives. Nat Commun. ^{3CitationPMID 29367645Open reference}(https://pubmed.ncbi.nlm.nih.gov/29367645/)

4. Hartig MB, et al. (2006). Diversity of pantothenate kinase-associated neurodegeneration. Neurology. ^{4CitationPMID 16567499Open reference}(https://pubmed.ncbi.nlm.nih.gov/16567499/)

5. Kumar K, et al. (2020). Iron metabolism in NBIA disorders. Nat Rev Neurol. ^{5CitationPMID 32838664Open reference}(https://pubmed.ncbi.nlm.nih.gov/32838664/)

6. Klopstock T, et al. (2019). Pantethine treatment in PKAN. Orphanet J Rare Dis. ^{6CitationPMID 31831012Open reference}(https://pubmed.ncbi.nlm.nih.gov/31831012/)

7. Dusi S, et al. (2014). Exome sequence reveals mutations in CoA biosynthetic genes. Brain. ^{7CitationPMID 24293368Open reference}(https://pubmed.ncbi.nlm.nih.gov/24293368/)

See Also

• Pantothenate Kinase-Associated Neurodegeneration

• Neurodegeneration with Brain Iron Accumulation

• Coenzyme A Biosynthesis Pathway

• Mitochondrial Dysfunction

• PANK2 Protein

• Iron Metabolism

• NBIA Disorders

External Links

• NCBI Gene: PANK1

• UniProt: Q8TE04

• Ensembl: ENSG00000167191

• OMIM: 606157

• GeneCards: PANK1

• NBIA Disorders Foundation

Background

The study of Pank1 — Pantothenate Kinase 1 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.